Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
Researchers analyzed data from patients with chronic hepatitis B to identify predictors of relapse in those who discontinued NAs and determined if existing rules for stopping NA therapy can be improved.
Increased utilization of HCV-positive liver allografts for LT is seen as one of the ways to counter national organ shortages, so researchers set out to better characterize the allografts that come from HCV-positive donors from specific regions.
Based on guidelines issued by the World Health Organizations in 2018, the American College of Physicians has issued best practice advice that simplifies and improves treatment of chronic hepatitis C virus.